Alliances
Boehringer Ingelheim and Eli Lilly released data from their Empagliflozin as Adjunctive to inSulin thErapy (EASE) Phase III trial in type 1 diabetes.
High Performance Nutrition, Inc. has announced an exclusive collaboration with Ambrosia Nutraceuticals, LLC. in bringing the next evolution in plant-based protein.
Boston Pharma went on a buying binge, licensing a slew of compounds from GlaxoSmithKline and Novartis in two separate deals.
In September OptiBiotix signs three more agreements
The American College of Foot and Ankle Surgeons (ACFAS) partnered with The Joint Commission, the Centers for Diseases Control and other healthcare specialty organizations on a three-year initiative, Adaptation and Dissemination for Outpatient Infection Prevention (ADOPT) Guidance, to help ensure patients are provided care in environments that minimizes or eliminates the risk of healthcare-associated infections.
TxCell SA today announces that the actions provided for by the agreement entered into between TxCell and Yorkville in July 2018
LGC Axolabs announces a significant investment at its site at Kulmbach, Germany, to expand the capacity of its specialist therapeutic oligonucleotide development solutions business and create a new GMP analytical capability.
Kangstem Biotech today announces the selection of MaSTherCell as its contract manufacturing partner for its European clinical trial of FURESTEM-AD(R).
Collaboration will focus on the development of a bespoke silicon array to enable high-throughput production of high-fidelity gene-length DNA
GO Therapeutics, headquartered in Cambridge, Mass., signed a licensing deal with Swiss-based Roche to develop antibodies for cancer.
PRESS RELEASES